A multicenter, retrospective, observational study assessing the real world treatment outcomes and healthcare resource utilization of transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous first-line lenalidomide or fixed bortezomib in Europe
Latest Information Update: 17 Nov 2021
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Lenalidomide (Primary) ; Bendamustine; Carfilzomib; Cisplatin; Corticosteroid; Cyclophosphamide; Cyclophosphamide; Daratumumab; Dexamethasone; Doxorubicin; Doxorubicin; Elotuzumab; Idarubicin; Ixazomib; Melphalan; Melphalan; Panobinostat; Pomalidomide; Prednisone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 17 Nov 2021 New trial record
- 01 Oct 2021 Results published in the Leukemia and Lymphoma